Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma

Business Wire June 29, 2021

Merck Appoints Michael Klobuchar Chief Strategy Officer

Business Wire June 24, 2021

LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Business Wire June 24, 2021

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

Business Wire June 22, 2021

Merck to Participate in the Guggenheim Biopharma Strategy Series

Business Wire June 17, 2021

Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All

Business Wire June 16, 2021

S&P Drifts Higher at Open

Press Releases June 9, 2021

Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19

Business Wire June 9, 2021

MSD Animal Health to Acquire Assets of LIC Automation Ltd.

Business Wire June 7, 2021

New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting

Business Wire June 7, 2021

LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial

Business Wire June 3, 2021

Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)

Business Wire June 3, 2021

Merck Announces Completion of Organon & Co. Spinoff

Business Wire June 3, 2021

Merck and Sanofi's First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States

Business Wire June 1, 2021

Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States

PR Newswire June 1, 2021

Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600

PR Newswire May 27, 2021

Merck Announces Third-Quarter 2021 Dividend

Business Wire May 25, 2021

Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

Business Wire May 20, 2021

Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations

PR Newswire May 17, 2021

Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Business Wire May 13, 2021